Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65

1.

LTBP3 promotes early metastatic events during cancer cell dissemination.

Deryugina EI, Zajac E, Zilberberg L, Muramatsu T, Joshi G, Dabovic B, Rifkin D, Quigley JP.

Oncogene. 2018 Apr;37(14):1815-1829. doi: 10.1038/s41388-017-0075-1. Epub 2018 Jan 19.

2.

Intratumoral Cancer Cell Intravasation Can Occur Independent of Invasion into the Adjacent Stroma.

Deryugina EI, Kiosses WB.

Cell Rep. 2017 Apr 18;19(3):601-616. doi: 10.1016/j.celrep.2017.03.064.

3.
4.

EGFR regulates the development and microarchitecture of intratumoral angiogenic vasculature capable of sustaining cancer cell intravasation.

Minder P, Zajac E, Quigley JP, Deryugina EI.

Neoplasia. 2015 Aug;17(8):634-49. doi: 10.1016/j.neo.2015.08.002.

5.

Tumor angiogenesis: MMP-mediated induction of intravasation- and metastasis-sustaining neovasculature.

Deryugina EI, Quigley JP.

Matrix Biol. 2015 May-Jul;44-46:94-112. doi: 10.1016/j.matbio.2015.04.004. Epub 2015 Apr 22. Review.

6.

Tissue-infiltrating neutrophils constitute the major in vivo source of angiogenesis-inducing MMP-9 in the tumor microenvironment.

Deryugina EI, Zajac E, Juncker-Jensen A, Kupriyanova TA, Welter L, Quigley JP.

Neoplasia. 2014 Oct 23;16(10):771-88. doi: 10.1016/j.neo.2014.08.013. eCollection 2014 Oct.

7.

Circular trimers of gelatinase B/matrix metalloproteinase-9 constitute a distinct population of functional enzyme molecules differentially regulated by tissue inhibitor of metalloproteinases-1.

Vandooren J, Born B, Solomonov I, Zajac E, Saldova R, Senske M, Ugarte-Berzal E, Martens E, Van den Steen PE, Van Damme J, Garcia-Pardo A, Froeyen M, Deryugina EI, Quigley JP, Moestrup SK, Rudd PM, Sagi I, Opdenakker G.

Biochem J. 2015 Jan 15;465(2):259-70. doi: 10.1042/BJ20140418.

8.

INPP4B suppresses prostate cancer cell invasion.

Hodgson MC, Deryugina EI, Suarez E, Lopez SM, Lin D, Xue H, Gorlov IP, Wang Y, Agoulnik IU.

Cell Commun Signal. 2014 Sep 25;12:61. doi: 10.1186/s12964-014-0061-y.

9.

Angiogenic capacity of M1- and M2-polarized macrophages is determined by the levels of TIMP-1 complexed with their secreted proMMP-9.

Zajac E, Schweighofer B, Kupriyanova TA, Juncker-Jensen A, Minder P, Quigley JP, Deryugina EI.

Blood. 2013 Dec 12;122(25):4054-67. doi: 10.1182/blood-2013-05-501494. Epub 2013 Oct 30.

10.

Tumor MMP-1 activates endothelial PAR1 to facilitate vascular intravasation and metastatic dissemination.

Juncker-Jensen A, Deryugina EI, Rimann I, Zajac E, Kupriyanova TA, Engelholm LH, Quigley JP.

Cancer Res. 2013 Jul 15;73(14):4196-211. doi: 10.1158/0008-5472.CAN-12-4495. Epub 2013 May 16.

11.

In vivo cleaved CDCP1 promotes early tumor dissemination via complexing with activated β1 integrin and induction of FAK/PI3K/Akt motility signaling.

Casar B, Rimann I, Kato H, Shattil SJ, Quigley JP, Deryugina EI.

Oncogene. 2014 Jan 9;33(2):255-68. doi: 10.1038/onc.2012.547. Epub 2012 Dec 3.

12.

Cell surface remodeling by plasmin: a new function for an old enzyme.

Deryugina EI, Quigley JP.

J Biomed Biotechnol. 2012;2012:564259. doi: 10.1155/2012/564259. Epub 2012 Oct 14. Review.

13.

The primacy of β1 integrin activation in the metastatic cascade.

Kato H, Liao Z, Mitsios JV, Wang HY, Deryugina EI, Varner JA, Quigley JP, Shattil SJ.

PLoS One. 2012;7(10):e46576. doi: 10.1371/journal.pone.0046576. Epub 2012 Oct 3.

14.

Targeting tumor cell invasion and dissemination in vivo by an aptamer that inhibits urokinase-type plasminogen activator through a novel multifunctional mechanism.

Botkjaer KA, Deryugina EI, Dupont DM, Gårdsvoll H, Bekes EM, Thuesen CK, Chen Z, Ploug M, Quigley JP, Andreasen PA.

Mol Cancer Res. 2012 Dec;10(12):1532-43. doi: 10.1158/1541-7786.MCR-12-0349. Epub 2012 Oct 4. Erratum in: Mol Cancer Res. 2013 Aug;11(8):964. Chen, Zhou [corrected to Chen, Zhuo].

15.

Blocking of CDCP1 cleavage in vivo prevents Akt-dependent survival and inhibits metastatic colonization through PARP1-mediated apoptosis of cancer cells.

Casar B, He Y, Iconomou M, Hooper JD, Quigley JP, Deryugina EI.

Oncogene. 2012 Aug 30;31(35):3924-38. doi: 10.1038/onc.2011.555. Epub 2011 Dec 19.

16.

Combating angiogenesis early: potential of targeting tumor-recruited neutrophils in cancer therapy.

Quigley JP, Deryugina EI.

Future Oncol. 2012 Jan;8(1):5-8. doi: 10.2217/fon.11.133. No abstract available.

17.

Activation of pro-uPA is critical for initial escape from the primary tumor and hematogenous dissemination of human carcinoma cells.

Bekes EM, Deryugina EI, Kupriyanova TA, Zajac E, Botkjaer KA, Andreasen PA, Quigley JP.

Neoplasia. 2011 Sep;13(9):806-21.

18.

Tumor-recruited neutrophils and neutrophil TIMP-free MMP-9 regulate coordinately the levels of tumor angiogenesis and efficiency of malignant cell intravasation.

Bekes EM, Schweighofer B, Kupriyanova TA, Zajac E, Ardi VC, Quigley JP, Deryugina EI.

Am J Pathol. 2011 Sep;179(3):1455-70. doi: 10.1016/j.ajpath.2011.05.031. Epub 2011 Jul 8.

19.

Evaluation of metastatic and angiogenic potentials of human colon carcinoma cells in chick embryo model systems.

Subauste MC, Kupriyanova TA, Conn EM, Ardi VC, Quigley JP, Deryugina EI.

Clin Exp Metastasis. 2009;26(8):1033-47. doi: 10.1007/s10585-009-9293-4. Epub 2009 Oct 20.

20.

Pleiotropic roles of matrix metalloproteinases in tumor angiogenesis: contrasting, overlapping and compensatory functions.

Deryugina EI, Quigley JP.

Biochim Biophys Acta. 2010 Jan;1803(1):103-20. doi: 10.1016/j.bbamcr.2009.09.017. Epub 2009 Oct 2. Review.

21.

Comparative analysis of metastasis variants derived from human prostate carcinoma cells: roles in intravasation of VEGF-mediated angiogenesis and uPA-mediated invasion.

Conn EM, Botkjaer KA, Kupriyanova TA, Andreasen PA, Deryugina EI, Quigley JP.

Am J Pathol. 2009 Oct;175(4):1638-52. doi: 10.2353/ajpath.2009.090384. Epub 2009 Sep 3.

22.

Functional role of cell surface CUB domain-containing protein 1 in tumor cell dissemination.

Deryugina EI, Conn EM, Wortmann A, Partridge JJ, Kupriyanova TA, Ardi VC, Hooper JD, Quigley JP.

Mol Cancer Res. 2009 Aug;7(8):1197-211. doi: 10.1158/1541-7786.MCR-09-0100. Epub 2009 Aug 11.

23.

Neutrophil MMP-9 proenzyme, unencumbered by TIMP-1, undergoes efficient activation in vivo and catalytically induces angiogenesis via a basic fibroblast growth factor (FGF-2)/FGFR-2 pathway.

Ardi VC, Van den Steen PE, Opdenakker G, Schweighofer B, Deryugina EI, Quigley JP.

J Biol Chem. 2009 Sep 18;284(38):25854-66. doi: 10.1074/jbc.M109.033472. Epub 2009 Jul 16.

24.

The cell surface glycoprotein CDCP1 in cancer--insights, opportunities, and challenges.

Wortmann A, He Y, Deryugina EI, Quigley JP, Hooper JD.

IUBMB Life. 2009 Jul;61(7):723-30. doi: 10.1002/iub.198. Review.

25.
26.

Chick embryo chorioallantoic membrane model systems to study and visualize human tumor cell metastasis.

Deryugina EI, Quigley JP.

Histochem Cell Biol. 2008 Dec;130(6):1119-30. doi: 10.1007/s00418-008-0536-2. Epub 2008 Nov 13. Review.

27.

Cell surface proteomics identifies molecules functionally linked to tumor cell intravasation.

Conn EM, Madsen MA, Cravatt BF, Ruf W, Deryugina EI, Quigley JP.

J Biol Chem. 2008 Sep 26;283(39):26518-27. doi: 10.1074/jbc.M803337200. Epub 2008 Jul 24.

28.

Human neutrophils uniquely release TIMP-free MMP-9 to provide a potent catalytic stimulator of angiogenesis.

Ardi VC, Kupriyanova TA, Deryugina EI, Quigley JP.

Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20262-7. Epub 2007 Dec 11.

29.

Functional analysis of matrix metalloproteinases and tissue inhibitors of metalloproteinases differentially expressed by variants of human HT-1080 fibrosarcoma exhibiting high and low levels of intravasation and metastasis.

Partridge JJ, Madsen MA, Ardi VC, Papagiannakopoulos T, Kupriyanova TA, Quigley JP, Deryugina EI.

J Biol Chem. 2007 Dec 7;282(49):35964-77. Epub 2007 Sep 25.

30.

Matrix metalloproteinases and tumor metastasis.

Deryugina EI, Quigley JP.

Cancer Metastasis Rev. 2006 Mar;25(1):9-34. Review.

PMID:
16680569
31.

Activity-based protein profiling implicates urokinase activation as a key step in human fibrosarcoma intravasation.

Madsen MA, Deryugina EI, Niessen S, Cravatt BF, Quigley JP.

J Biol Chem. 2006 Jun 9;281(23):15997-6005. Epub 2006 Apr 12.

32.

Unexpected effect of matrix metalloproteinase down-regulation on vascular intravasation and metastasis of human fibrosarcoma cells selected in vivo for high rates of dissemination.

Deryugina EI, Zijlstra A, Partridge JJ, Kupriyanova TA, Madsen MA, Papagiannakopoulos T, Quigley JP.

Cancer Res. 2005 Dec 1;65(23):10959-69.

33.

Proangiogenic role of neutrophil-like inflammatory heterophils during neovascularization induced by growth factors and human tumor cells.

Zijlstra A, Seandel M, Kupriyanova TA, Partridge JJ, Madsen MA, Hahn-Dantona EA, Quigley JP, Deryugina EI.

Blood. 2006 Jan 1;107(1):317-27. Epub 2005 Sep 20.

34.

Prointegrin maturation follows rapid trafficking and processing of MT1-MMP in Furin-Negative Colon Carcinoma LoVo Cells.

Deryugina EI, Ratnikov BI, Yu Q, Baciu PC, Rozanov DV, Strongin AY.

Traffic. 2004 Aug;5(8):627-41.

35.

Collagenolysis-dependent angiogenesis mediated by matrix metalloproteinase-13 (collagenase-3).

Zijlstra A, Aimes RT, Zhu D, Regazzoni K, Kupriyanova T, Seandel M, Deryugina EI, Quigley JP.

J Biol Chem. 2004 Jun 25;279(26):27633-45. Epub 2004 Apr 5.

36.

Aberrant, persistent inclusion into lipid rafts limits the tumorigenic function of membrane type-1 matrix metalloproteinase in malignant cells.

Rozanov DV, Deryugina EI, Monosov EZ, Marchenko ND, Strongin AY.

Exp Cell Res. 2004 Feb 1;293(1):81-95.

PMID:
14729059
37.

Membrane type-1 matrix metalloproteinase stimulates tumour cell-induced platelet aggregation: role of receptor glycoproteins.

Alonso-Escolano D, Strongin AY, Chung AW, Deryugina EI, Radomski MW.

Br J Pharmacol. 2004 Jan;141(2):241-52. Epub 2003 Dec 22.

39.
40.

Compensation mechanism in tumor cell migration: mesenchymal-amoeboid transition after blocking of pericellular proteolysis.

Wolf K, Mazo I, Leung H, Engelke K, von Andrian UH, Deryugina EI, Strongin AY, Bröcker EB, Friedl P.

J Cell Biol. 2003 Jan 20;160(2):267-77. Epub 2003 Jan 13.

42.
44.

The hemopexin-like C-terminal domain of membrane type 1 matrix metalloproteinase regulates proteolysis of a multifunctional protein, gC1qR.

Rozanov DV, Ghebrehiwet B, Postnova TI, Eichinger A, Deryugina EI, Strongin AY.

J Biol Chem. 2002 Mar 15;277(11):9318-25. Epub 2001 Dec 31.

45.

An alternative processing of integrin alpha(v) subunit in tumor cells by membrane type-1 matrix metalloproteinase.

Ratnikov BI, Rozanov DV, Postnova TI, Baciu PG, Zhang H, DiScipio RG, Chestukhina GG, Smith JW, Deryugina EI, Strongin AY.

J Biol Chem. 2002 Mar 1;277(9):7377-85. Epub 2001 Dec 10.

46.
47.

Characterization of matrix metalloproteinase-26, a novel metalloproteinase widely expressed in cancer cells of epithelial origin.

Marchenko GN, Ratnikov BI, Rozanov DV, Godzik A, Deryugina EI, Strongin AY.

Biochem J. 2001 Jun 15;356(Pt 3):705-18.

49.

Matrix-dependent proteolysis of surface transglutaminase by membrane-type metalloproteinase regulates cancer cell adhesion and locomotion.

Belkin AM, Akimov SS, Zaritskaya LS, Ratnikov BI, Deryugina EI, Strongin AY.

J Biol Chem. 2001 May 25;276(21):18415-22. Epub 2001 Mar 2.

50.

MT1-MMP initiates activation of pro-MMP-2 and integrin alphavbeta3 promotes maturation of MMP-2 in breast carcinoma cells.

Deryugina EI, Ratnikov B, Monosov E, Postnova TI, DiScipio R, Smith JW, Strongin AY.

Exp Cell Res. 2001 Feb 15;263(2):209-23.

PMID:
11161720

Supplemental Content

Loading ...
Support Center